Microbot Medical Inc.

Equities

MBOT

US59503A2042

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-22 EDT			5-day change	1st Jan Change
1.08 ^USD	+9.09%		+16.12%	-34.15%

05-15	Microbot Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-29	Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health	CI

Microbot Medical Inc. Announces the Expansion of its Global IP Portfolio by Receiving a Grant of Protection from the Japan Patent Office

June 22, 2023 at 08:36 am

Microbot Medical Inc. announced the expansion of its global IP portfolio by receiving a Grant of Protection from the Japan Patent Office for a Design Patent covering the innovative industrial design of the robotic drive of the LIBERTY Robotic Surgical System. Microbot's IP portfolio for LIBERTY and its related technologies includes 19 patents issued/allowed and 41 applications pending. This Design Patent complements previously received protection in Japan covering the unique design of the LIBERTY Robosis System remote controller.

Similar Design Patents were granted in the U.S., Europe, and Israel.

Latest news about Microbot Medical Inc.

Microbot Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health	04-29	CI
HC Wainwright Adjusts Microbot Medical's Price Target to $7 From $8, Keeps Buy Rating	04-16	MT
Microbot Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Microbot Medical Submits US FDA Application to Start Human Clinical Trial for Robotic Surgical System	02-05	MT
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US	02-05	CI
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study	01-18	CI
Sector Update: Health Care Stocks Ease Friday Afternoon	12-29	MT
Microbot Medical to Exercise Outstanding Preferred Investment Options for $2.7 Million	12-29	MT
Sector Update: Health Care Stocks Rise in Late Afternoon	12-28	MT
Microbot Medical Says GLP Preclinical Study of Liberty Endovascular Robotic Surgical System Met Objectives; Shares Rise	12-28	MT
Sector Update: Health Care Stocks Advance Thursday Afternoon	12-28	MT
Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met	12-28	CI
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY Endovascular Robotic Surgical System for Telerobotic	12-14	CI
Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study	12-07	CI
Microbot Medical Inc. Announces Executive Changes	11-21	CI
Microbot Medical Files $75 Million Shelf	11-20	MT
Microbot Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process	11-13	CI
Sector Update: Health Care Stocks Mixed Late Wednesday Afternoon	11-08	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	11-08	MT
Microbot Medical Gets Registered Trademark From US Patent and Trademark Office	11-08	MT
Microbot Medical Inc. Approves Ratification of Brightman Almagor Zohar & Co. as Independent Registered Public Accounting Firm	11-06	CI
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from Its Pivotal Pre-Clinical Study	23-10-31	CI
Microbot Medical Says Court Dismisses Counterclaim Against Company in Short-Swing Lawsuit	23-10-19	MT

Chart Microbot Medical Inc.

Duration

Period

More charts

Company Profile

Microbot Medical Inc. is a pre-clinical medical device company. The Company is specializing in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is primarily focused on leveraging its robotic technologies with surgical robotics to improve surgical outcomes for patients. Its technological platforms include LIBERTY and NovaCross. Using its LIBERTY Endovascular Robotic Surgical System, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the bodyâs vasculature. It eliminates the need for capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. LIBERTY Endovascular Robotic Surgical System addresses the needs of interventional cardiology, interventional radiology and interventional neuroradiology markets.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.08 USD

Average target price

7 USD

Spread / Average Target

+548.15%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MICROBOT MEDICAL INC.	-34.15%	15.55M
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+44.36%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B

Other Biotechnology & Medical Research